Literature DB >> 9621513

Mutational analysis of the RET proto-oncogene in 71 Japanese patients with medullary thyroid carcinoma.

S Shirahama1, K Ogura, H Takami, K Ito, T Tohsen, A Miyauchi, Y Nakamura.   

Abstract

Multiple endocrine neoplasia types 2A and 2B (MEN2A and MEN2B) and familial medullary thyroid carcinomas (FMTC) are caused by germline mutations in the RET proto-oncogene. To investigate the spectrum of RET mutations among Japanese patients, we screened the RET gene in 71 patients with thyroid carcinomas. The panel included representatives of 44 families carrying FMTC or MEN2, 22 sporadic medullary thyroid carcinomas (MTCs), and five MTCs without familial information. Mutations in nucleotide sequences encoding one of three specific cysteine residues in the extracellular domain of the RET protein were found in 33 of the 34 MEN2A patients and in five of the six FMTC patients examined. A mutation at codon 918, causing the substitution of threonine for methionine in the tyrosine kinase domain of the protein, was found in germline DNAs of all four patients with MEN2B and in two of the 22 patients with sporadic MTCs; codon 918 was mutated somatically in tumor DNAs from three other sporadic cases. Germline mutations of codon 768, GAG to GAC (Glu to Asp), were detected in one FMTC, in one patient with sporadic MTC, and in one of the patients without familial information. Two somatic mutations, an Asp to Gly substitution at codon 631 and a Cys to Arg substitution at codon 634, had not been reported previously. Of five germline mutations found among the 22 sporadic cases, four were confirmed as de novo mutations since in each case neither parent carried the mutation. As nearly one-fourth of the patients with sporadic MTCs carried germline mutations and 50% of their children are expected to develop MTC and other endocrine tumors, these results indicated the importance of careful clinical surveillance of family members of any patient with MTC.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9621513     DOI: 10.1007/s100380050048

Source DB:  PubMed          Journal:  J Hum Genet        ISSN: 1434-5161            Impact factor:   3.172


  10 in total

1.  The finding of a somaticdeletion in RET exon 15 clarified the sporadic nature of amedullary thyroid carcinoma suspected to be familial.

Authors:  J Oriola; I Halperin; F Rivera-Fillat; H Donis-Keller
Journal:  J Endocrinol Invest       Date:  2002-01       Impact factor: 4.256

2.  A Drosophila model of multiple endocrine neoplasia type 2.

Authors:  Renee D Read; Paul J Goodfellow; Elaine R Mardis; Nancy Novak; Jon R Armstrong; Ross L Cagan
Journal:  Genetics       Date:  2005-06-18       Impact factor: 4.562

Review 3.  RET proto-oncogene mutations in thyroid carcinomas: clinical relevance.

Authors:  F Pacini; R Elisei; C Romei; A Pinchera
Journal:  J Endocrinol Invest       Date:  2000-05       Impact factor: 4.256

Review 4.  Medullary thyroid carcinoma and multiple endocrine neoplasia type 2.

Authors:  Hiroshi Takami
Journal:  Endocr Pathol       Date:  2003       Impact factor: 3.943

5.  First description of parathyroid disease in multiple endocrine neoplasia 2A syndrome.

Authors:  James C Sisson; Thomas J Giordano; Victoria M Raymond; Gerard M Doherty; Stephen B Gruber
Journal:  Endocr Pathol       Date:  2008       Impact factor: 3.943

Review 6.  RET and neuroendocrine tumors.

Authors:  Yoshiki Murakumo; Mayumi Jijiwa; Naoya Asai; Masatoshi Ichihara; Masahide Takahashi
Journal:  Pituitary       Date:  2006       Impact factor: 3.599

7.  Primary hyperparathyroidism: an overview.

Authors:  Jessica Mackenzie-Feder; Sandra Sirrs; Donald Anderson; Jibran Sharif; Aneal Khan
Journal:  Int J Endocrinol       Date:  2011-06-02       Impact factor: 3.257

8.  Predominant RET Germline Mutations in Exons 10, 11, and 16 in Iranian Patients with Hereditary Medullary Thyroid Carcinoma.

Authors:  Mehdi Hedayati; Marjan Zarif Yeganeh; Sara Sheikhol Eslami; Shekoofe Rezghi Barez; Laleh Hoghooghi Rad; Fereidoun Azizi
Journal:  J Thyroid Res       Date:  2011-06-13

9.  Localization of a target region of allelic loss to a 1-cM interval on chromosome 16p.13.13 in hepatocellular carcinoma.

Authors:  M Koyama; H Nagai; K Bando; M Ito; Y Moriyama; M Emi
Journal:  Jpn J Cancer Res       Date:  1999-09

10.  Genetic screening for monogenic hypertension in hypertensive individuals in a clinical setting.

Authors:  Minghui Bao; Ping Li; Qifu Li; Hui Chen; Ying Zhong; Shuangyue Li; Ling Jin; Wenjie Wang; Zhenzhen Chen; Jiuchang Zhong; Bin Geng; Yuxin Fan; Xinchun Yang; Jun Cai
Journal:  J Med Genet       Date:  2020-06-19       Impact factor: 6.318

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.